注射用重组人尿激酶原治疗急性心肌梗死疗效观察

Observation Effect on Recombinant Human Prourokinase for Injection Treatment of Acute Myocardial

目的：观察注射用重组人尿激酶原溶栓治疗急性ST段抬高型心肌梗死的开通率及安全性。方法采用自身对照、开放单一治疗试验设计方案，对符合入选标准的患者均给予注射用重组人尿激酶原治疗。溶栓之前,静脉注射肝素60 U/kg，后以12 U/kg/h维持，监测aPTT并维持50～70 s；静脉肝素维持时间应至少为48 h。结果10例患者再通率100%，未见出血风险。结论注射用重组人尿激酶原开通率高，安全性好。

Objective Observe recombinant human prourokinase for injection thrombolytic therapy in acute ST-segment elevation patency myocardial infarction and safety. Methods Use of self-control, open monotherapy trial design, patients met the inclusion criteria were given injection of recombinant human urokinase thrombolytic therapy. Before injection injection of recombinant human prourokinase, intravenous heparin 60 U/kg, after to 12 U/kg/hr to maintain, monitor and maintain aPTT 50~70 seconds, intravenous heparin duration should be at least 48 hours. Results 10 patients recanalization rate of 100%, no risk of bleeding. Conclusion Injection with urokinase of restructuring the original take rate is high, good safety.